3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

@article{Cheung19983F8MA,
  title={3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.},
  author={Nai-Kong V Cheung and Brian H. Kushner and Samuel D. J. Yeh and Steve M. Larson},
  journal={International journal of oncology},
  year={1998},
  volume={12 6},
  pages={
          1299-306
        }
}
3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 43 CITATIONS

Principles of Cancer Biotherapy 5

VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED